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Purpose. To correlate the radiological aspects of metastases, the response to chemotherapy, and patient outcome in disseminated
childhood medulloblastoma. Patients and Methods. This population-based study concerned 117 newly diagnosed children with
disseminated medulloblastoma treated at the Institute Gustave Roussy between 1988 and 2008. Metastatic disease was assessed
using the Chang staging system, their form (positive cerebrospinal ﬂuid (CSF), nodular or laminar), and their extension (positive
cerebrospinal ﬂuid, local, extensive). All patients received preirradiation chemotherapy. Results. The overall survival did not diﬀer
according to Chang M-stage. The 5-year overall survival was 59% in patients with nodular metastases compared to 35% in
those with laminar metastases. The 5-year overall survival was 76% in patients without disease at the end of pre-irradiation
chemotherapy compared to 34% in those without a complete response (P = 0.0008). Conclusions. Radiological characteristics
of metastases correlated with survival in patients with medulloblastoma. Complete response to sandwich chemotherapy was a
strong predictor of survival.
1.Introduction
Medulloblastoma (MB) is the most common malignant
brain tumor of childhood. It has a propensity for lep-
tomeningeal spread via the cerebrospinal ﬂuid (CSF) circula-
tion, and approximately 30–35% of the patients present with
evidence of metastatic disease [1].
Currently, patients with disseminated medulloblastoma
are classiﬁed according to Chang’s operative staging system
[2], where the extent of metastasis is subdivided into M0 (no
metastasis), M1 (presence of tumor cells in the CSF), M2
(nodular seeding in the cerebellar or cerebral subarachnoid
space or in the third or lateral ventricle), M3 (metastasis
in spinal subarachnoid space), and M4 (metastases outside
the cerebrospinal axis). This sensitive operative system was
initially determined from operative records and autopsy
specimens and has been later adapted to modern imaging
techniques such as MRI. Neither the extent nor the various
aspects of the metastases are taken into account, and only
thelocationisconsidered.Therelevanceofintracranial(M2)
and spinal (M3) leptomeningeal spread for classiﬁcation as
high-risk disease is unequivocal and the outcome for M2
patients is not signiﬁcantly diﬀerent from M3 patients [1, 3].
Since the original classiﬁcation in 1969 that did not separate
theoutcomeofpatientswithM0andM1disease,thereisstill
some uncertainty about the prognostic impact of M1 stage
[3–8]. In addition, the assessment of response to therapy
of the metastatic disease is often diﬃcult and limited by
the sensitivity of MRI [9]. Following personal observations,
we made the hypothesis that metastases could be further2 International Journal of Surgical Oncology
subclassiﬁed on the basis of speciﬁc phenotypic criteria with
potential correlation with patient outcome. In the present
study, we investigated whether the MRI appearances of
metastases and the response to chemotherapy could predict
survival in disseminated medulloblastoma.
2. Methods
2.1. Patients. The medical records and imaging of all chil-
dren with newly diagnosed disseminated medulloblastoma
treated at our institution from 1988 to 2008 were reviewed.
Inclusion criteria for this study were (1) children <18years
at diagnosis and (2) complete medical records including
pre- and postoperative cerebral imaging, analysis of CSF,
and interpretable cranial and spinal MRI scans. Exclusion
criteriawere(1)recurrentmedulloblastomaand(2)previous
treatment for malignancy.
Parents/guardians gave written informed consent for the
retrospective analysis of clinical data according to the IRB
of the Gustave Roussy Institute. For patients entered into
ongoing protocols, written informed consent was obtained
from their parents/guardians.
2.2. Treatment. Children were treated with diﬀerent proto-
cols. All patients received the same sandwich chemotherapy,
with a combination of carboplatin and etoposide [10].
The treatment varied with the time and was stratiﬁed
by age. Patients older than 5years of age were treated by
conventional chemotherapy with craniospinal irradiation
(CSI) (30–35 gray (Gy)) [3, 11] or sequential HDCT with
ASCT followed by standard dose CSI (36Gy) [12, 13].
Children younger than 5years of age were treated by high-
dose chemotherapy (HDCT) with autologous stem cell
transplantation (ASCT) followed by local radiation therapy
to the posterior fossa (50–55Gy) [12] or sequential HDCT
with ASCT followed by reduced dose CSI [14].
2.3.ClassiﬁcationDeﬁnitionandFollowupEvaluations. Cyto-
logical analysis of CSF collected by lumbar puncture was
performed between the 7th and 15th postoperative day. The
presence of metastases was evaluated by the initial cranial
and spinal MRI according to Chang’s staging system [2].
Metastases were described according to their phenotype
(nodular, laminar) (Figure 1) and their extension (localized,
extensive). Nodular metastases were deﬁned as an abnormal
deposit with gadolinium enhancement measurable in two
dimensions. Laminar metastases were deﬁned as abnormal
appearances with gadolinium enhancement that were not
measurable in two dimensions. Metastases were classiﬁed as
laminarwheretherewascoexistenceofmetastasesoflaminar
and nodular appearance. Extent of disease was deﬁned as
“localized” in the case of a single metastasis or in the
samearea(e.g.,periventricular,spinalconus)and“extensive”
when there was more than one metastasis in 2 diﬀerent
sites. According to these radiological criteria, we considered
two classiﬁcations: qualitative classiﬁcation (positive CSF,
nodular, laminar) and quantitative classiﬁcation (positive
CSF, localized, extensive).
Nodular phenotype Laminar phenotype
Figure 1: Metastasis phenotype.
After each cycle of chemotherapy, cranial and spinal MRI
wereperformed,andchildrenunderwentcytologicalanalysis
of CSF if initially positive for tumor cells.
2.4.End-PointsandStatisticalAnalysis. Theﬁnalanalysiswas
performed in April 2009. Patients were considered as having
incomplete followup if they were not seen 6 months before
the time of analysis.
The potential association of each classiﬁcation (Chang’s,
qualitative and quantitative classiﬁcations) with overall sur-
vival and with early complete response was investigated as
well as the inﬂuence of age at diagnosis (age <5years or
age ≥5years) and treatment.
Overall Survival (OS) was deﬁned as the time from the
date of diagnosis to the date of death or last contact and
Progression-Free Survival (PFS) from the date of diagnosis
to the date of ﬁrst recurrence or death.
Early response to chemotherapy was evaluated after the
whole preirradiation chemotherapy. Complete response was
deﬁned as the total disappearance of a residual primary
tumor and metastases (radiological and/or CSF metastases)
during or at the end of chemotherapy. Because classical
criteria of partial response (> or <50%) are diﬃcult to
apply to both leptomeningeal lesions and CSF involvement,
data were classiﬁed as partial response when radiological
response of lesions was observed in combination with a
negative CSF cytology, as stable disease in the case of (a)
positive CSF at diagnosis (M1) which remained positive or
(b) stable radiological imaging (without progression in CSF
cytology), and as progressive disease when progression on
imaging was noted or when negative CSF cytology became
positive.
Results are expressed as percentages or medians (range).
Response rates were compared using nonparametric tests:
chi-square or exact Fisher test. OS and PFS were estimated
using the Kaplan Meier method [15] and Rothman’s 95%
Conﬁdence Intervals [95% CI] [16] and compared using
the logrank test. Median followup was estimated using the
inverse Kaplan-Meier method [17]. In a multivariate analysis
of OS, the Hazard Ratios (HRs) of death and their 95% CI
were estimated using the Cox proportional hazards model
[18]. In a multivariate analysis of complete response, theInternational Journal of Surgical Oncology 3
Table 1: Qualitative and quantitative classiﬁcations according to
Chang’s.
N (%)
Chang’s classiﬁcation M1
22 (19%)
M2
25 (21%)
M3
70 (60%)
Qualitative classiﬁcation
Positive CSF: 22 (19%) 22 (100%)
Nodular: 36 (31%) 15 (42%) 21 (58%)
Laminar: 59 (50%) 10 (17%) 49 (83%)
Quantitative classiﬁcation
Positive CSF: 22 (19%) 22 (100%)
Localized: 26 (22%) 18 (69%) 8 (31%)
Extensive: 69 (59%) 7 (10%) 62 (90%)
Hazard Ratios (HRs) of event and their 95% CI were
estimated using logistic regression. All reported P values are
twosided. P values below 5% were considered signiﬁcant.
Analyses were performed with SAS version 9.1.
3. Results
3.1. Patients. 117 children with disseminated medulloblas-
tomawereeligibleforthisstudy.Themedianageatdiagnosis
was 4 years (range, 0–14), and 68 (58%) were less than 5
years. There were 82 males (70%) and 35 females (30%).
Thirty-eight children (32%) were treated by conventional
chemotherapy (etoposide and carboplatin) followed by CSI
at “conventional” doses. HDCT with ASCT followed by
local radiation therapy to the posterior fossa was performed
in 10 patients (9%). Forty-seven (40%) children received
sequential HDCT with ASCT followed by reduced dose CSI,
and 22 patients (19%) were treated with sequential HDCT
with ASCT followed by standard dose CSI.
Table 1 presents the pattern of metastatic disease accord-
ing to the 3 classiﬁcation systems. Among the 36 patients
with nodular metastasis, 15 (42%) were Chang stage M2
stage and 21 (58%) were M3 stage. For the 51 patients with
laminar metastasis, 10 (17%) were M2 and 49 (83%) were
M3. Of the 26 children with localized metastasis, 18 (69%)
were M2 stage and 8 (31%) were M3, and of the 69 with
extensive metastasis, 7 (10%) were M2 stage and 62 (90%)
were M3. Sixty-one percent of patients older than 5 years of
age had nodular metastases.
3.2. Progression-Free and Overall Survival. The median fol-
lowup was 8 years (range, 1–17). For 19 children, the
followup was incomplete with a median time between the
last followup and the time of analysis of 22 months (range,
7–78 months). Sixty-six deaths were noted: 64 patients from
disease and 2 from treatment-related toxicity. Relapse or
death as ﬁrst event occurred in 72 children. There were two
casesofsecondtumor,onewithbrainstemglioma58months
after the initial diagnosis and one renal carcinoma 106
months after the initial diagnosis. The estimated ﬁve-year
overall survival (OS) and progression-free survival (PFS)
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Figure 2: Overall survival according to the early response to
sandwich chemotherapy.
rates among the 117 children were 45% (95% CI: 36–55%)
and 38% (CI 95%: 29–47%), respectively.
3.3. Response to Sandwich Chemotherapy. The early response
rate to sandwich chemotherapy is given in Table 2.T h e
median delay from the date of diagnosis to the date of
assessment of response to sandwich chemotherapy was 67
days (range, 26–340). A complete response to sandwich
chemotherapy was observed in 27 (23%) of the 117 patients.
OS was higher among these 27 patients than among the
90 patients with residual disease, P = 0.0008 (Figure 2).
The corresponding 5-year OS rates were 76% and 34%,
respectively.
3.4.UnivariateandMultivariateAnalysis. Univariateanalysis
identiﬁed agelessthan5yearsassigniﬁcantlyassociatedwith
poor survival and poor early response rate. Overall survival
was lower for children younger than 5 years than for those
aged 5 or more (HR: 2.5 (1.5–4.2), P = 0.001). The HR
of no early complete response for children younger than
5 years compared to children of 5 years or more was 3.1
(1.3–7.5), P = 0.014. There was no signiﬁcant association
between initial treatment and OS (P = 0.290). Thus the
multivariateanalysiswasadjustedforage(<5years/ ≥5years)
only.
In the univariate analysis, the qualitative classiﬁcation
was signiﬁcantly correlated (P = 0.04) with OS (Table 3). OS
was higher for children with nodular metastasis (HR = 0.6
(0.3–1.2)) and lower for children with laminar metastasis
(HR = 1.3 (0.7–2.5)), compared to children with positive
CSF. The ﬁve-year OS rates were 47%, 59%, and 35% for
patients with positive CSF, nodular metastases, and laminar
metastases, respectively (Figure 3). There was no signiﬁcant4 International Journal of Surgical Oncology
Table 2: Univariate and multivariate analysis of early Complete Response (CR) to sandwich chemotherapy.
Univariate analysis Multivariate analysis
CR (%) HR IC (95%) P value HR IC (95%) P value
Chang’staging
M1 (n = 22) 11 (50%) 1
0.006
1
0.002 M2 (n = 25) 3 (12%) 7.3 1.7–31.8 9.8 2.0–46.9
M3 (n = 70) 13 (19%) 4.4 1.6–12.3 6.7 2.1–21.6
Qualitative classiﬁcation
Positive CSF (n = 22) 11 (50%) 1 0.005 1 0.002
Nodular (n = 36) 8 (22%) 3.5 1.1–11.0 6.3 1.7–23.7
Laminar (n = 59) 8 (14%) 6.4 2.1–19.5 8.1 2.4–27.2
Quantitative classiﬁcation
Positive CSF (n = 22) 11 (50%) 1
0.003
1
0.001 Localized (n = 26) 7 (27%) 2.7 0.8–9.0 4.2 1.1–15.8
Extensive (n = 69) 9 (13%) 6.7 2.2–19.8 9.7 2.9–32.9
correlation of OS with either the Chang classiﬁcation
(P = 0.95) or the quantitative classiﬁcation (P = 0.12).
According to Chang’s staging system, the ﬁve-year OS rates
were 47%, 51%, and 42% for M1, M2, and M3 stage,
respectively (Figure 4).
In the multivariate analyses, after adjustment on age,
none of the three classiﬁcations was associated with OS,
even when qualitative and quantitative classiﬁcations were
combined.
Chang’s, qualitative and quantitative classiﬁcations are
signiﬁcantly associated with early complete response rate
after sandwich chemotherapy in univariate and multivariate
analyses (Table 2).
4. Discussion
Inthisretrospectivereviewof117childrenwithdisseminated
medulloblastoma treated at a single institution, we found
that the phenotype of metastasis had an impact on OS.
Patient with nodular metastasis had a better survival than
the patients with other metastatic groups. Diﬀuse metastases
(i.e., laminar metastases, M1 disease) were associated with
a more aggressive disease than those with nodular disease.
The impact of the phenotype of metastases on OS has
not been published previously. In this study, the qualitative
classiﬁcation was signiﬁcantly correlated with OS (P = 0.04)
in univariate but not in multivariate analysis. Since the
phenotype of the metastases was associated with age in our
study, we may have lost its eﬀect on prognosis by adjusting
the multivariate analysis on age. Moreover, since response
to chemotherapy is associated with the phenotype of the
metastases and is the strongest prognostic factor identiﬁed
in our study, diﬀerent treatment policies according to age
may confound the results of the multivariate analysis. We
can hypothesize that there are intrinsic biological diﬀerences
linked to age that drive the phenotype of the metastases
and their response to chemotherapy. These results should be
conﬁrmed in a large prospective study.
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Figure 3: Overall survival according to qualitative classiﬁcation.
The Chang’s operative staging system was initially shown
to predict outcome according to the T stage, that is, tumor
size and invasion, although recent publications have failed to
show an impact of T stage on survival [19, 20]. The Chang
system did not, however, include prognostic information
with respect to the diﬀerent M stages. Subsequent studies
have clearly shown the adverse prognostic factor of the
presence of metastasis. In many studies, the high-risk group
was deﬁned as Chang M2 and M3 stage, and the outcome for
M2 patients was not signiﬁcantly diﬀerent from M3 patients
[1, 3, 8, 21, 22]. There remained doubt, however, about the
prognostic signiﬁcance of M1 stage and whether patientsInternational Journal of Surgical Oncology 5
Table 3: Univariate and multivariate analysis of Overall Survival (OS).
Univariate analysis Multivariate analysis
5-year OS HR IC (95%) P value HR IC (95%) P value
Chang’s classiﬁcation
M1 (n = 22) 47% 1
0.95
1
0.73 M2 (n = 25) 51% 0.9 0.4–1.9 0.9 0.4–2.0
M3 (n = 70) 42% 1.0 0.5–1.9 1.2 0.6–2.2
Qualitative classiﬁcation
Positive CSF (n = 22) 47% 1 0.04 1 0.17
Nodular (n = 36) 59% 0.6 0.3–1.2 0.7 0.3–1.6
Laminar (n = 59) 35% 1.3 0.7–2.5 1.3 0.7–2.4
Quantitative classiﬁcation
Positive CSF (n = 22) 47% 1
0.12
1
0.16 Localized (n = 26) 65% 0.6 0.3–1.3 0.7 0.3–1.5
Extensive (n = 69) 36% 1.2 0.6–2.2 1.3 0.7–2.4
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Figure 4: Overall survival according to Chang’s classiﬁcation.
with M1 disease constituted a truly high-risk group. Several
studies have found an intermediate risk for M1 metastases,
with outcomes rates lower than in M0 but superior to M2/3
dissemination [3–8]. In our study, we found that patients
with M1 disease (with/without residual mass) are truly
high-risk patients with no signiﬁcantly diﬀerent outcome
compared with solid metastases. Sanders et al. showed
recently that patients with M1 disease have reduced rates of
EFSandOScomparedtothosewithM0disease[7].Children
younger than 3 years of age with M1 MB had signiﬁcantly
decreasedEFScomparedtothosewithM0diseaseandinfact
fared as poorly as those with macroscopic metastatic disease
(M2/M3)[7].Ontheotherhand,intheGermanHIT91trial,
patients with M1 disease had a similar outcome to those with
M0 with 3-year EFS of 72%, 65%, and 30% for patients with
M0, M1, and M2/3 disease, respectively [23].
One has to take into account the type of treatment since
the HIT’91 trial randomizing sandwich against maintenance
chemotherapy found a better outcome for the M1 patients
in the maintenance arm (i.e., with early radiotherapy) and a
better outcome for the M2/M3 patients in the preirradiation
chemotherapy arm. Since our policy was to give the same
sandwich chemotherapy to all patients, this may have been
detrimental to M1 patients, while beneﬁcial for M2/M3
patients.
The earlier response to chemotherapy seems to be
important for outcome. We found that patients in complete
remission after preirradiation had signiﬁcantly a better OS
compared those not in complete remission. The prognostic
impactofearlyresponsetochemotherapyfoundinourstudy
is consistent with others’ reports [24, 25].
In summary, ﬁndings in this study suggest that the
phenotype of metastases should be taken into account when
describing a population of children with metastatic medul-
loblastomas. If conﬁrmed by further prospective studies,
this report suggests that treatment strategies for metastatic
medulloblastoma need to be reﬁned taking into account the
nature as well as the presence of metastases.
The early response to sandwich chemotherapy may
also help us to stratify the treatment of children with
disseminated medulloblastoma. Further studies are justiﬁed
to ﬁnd biological correlates with respect to the metastatic
phenotype.
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